As rivals press in, Stanford spinout Forty Seven burnishes its prospects from an impressive PhIb
Irv Weissman’s anti-CD47 cancer drug is in the spotlight today with early but remarkable data published in the NEJM to underscore its potential as a new cancer therapy.
The legendary Stanford investigator founded Forty Seven $FTSV to see if it could take the lead among biotechs working on conquering the ‘don’t-eat-me’ signal emitted by the protein CD47 on cancer cells. Combined with rituximab, their combo elicited a positive response in half of the cancer patients they tested it on, with 8 of those patients achieving a complete response — with no sign of residual disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
